Comparative tolerability of therapies for ulcerative colitis

Area of Science:

• Pharmacology
• Gastroenterology
• Internal Medicine

Background:

• Ulcerative colitis (UC) treatment involves various drug classes with distinct efficacy and safety profiles.
• Conventional synthetic glucocorticoids are widely used but associated with systemic adverse effects.
• Newer topical corticosteroids and other agents aim for improved tolerability in UC management.

Purpose of the Study:

• To review the clinical pharmacology of UC medications.
• To compare the adverse events and tolerability of commonly used UC drugs.
• To inform treatment decisions by highlighting drug-specific risks and benefits.

Main Methods:

• Literature review of clinical pharmacology studies.
• Analysis of reported adverse events for UC therapeutics.
• Comparative assessment of drug tolerability based on available data.

Main Results:

• Corticosteroids impact multiple organ systems; newer topical agents offer a better safety profile.
• Sulfasalazine (5-aminosalicylic acid plus sulfapyridine) adverse effects are dose-related and linked to the sulfapyridine component.
• Azathioprine/mercaptopurine adverse events depend on dose, metabolism, and thiopurine methyltransferase (TPMT) genotype.
• High-dose cyclosporine has significant adverse effects, while low-dose oral use is better tolerated.

Conclusions:

• Assessing and comparing adverse event incidence across UC medications is challenging.
• The expanding therapeutic options for UC advance disease understanding.
• Future research is expected to yield more effective and safer UC treatments.